Skip to main content
Erschienen in: European Radiology 4/2018

15.11.2017 | Magnetic Resonance

Application of DWIBS in malignant lymphoma: correlation between ADC values and Ki-67 index

verfasst von: Mengtian Sun, Jingliang Cheng, Yong Zhang, Jie Bai, Feifei Wang, Yun Meng, Zhenqian Li

Erschienen in: European Radiology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Objectives

We investigated the correlation between the apparent diffusion coefficient (ADC) and Ki-67 index using diffusion-weighted whole-body imaging with background body signal suppression (DWIBS), and their utility in evaluating malignant lymphoma cell proliferation.

Materials and Methods

Seventy-four patients with malignant lymphoma underwent DWIBS within 1 week before pathological confirmation. The ADC value was measured at the site of the pathological examination, and specimens were also stained with Ki-67. The ADC values and Ki-67 indices in aggressive non-Hodgkin's lymphoma (NHL), indolent NHL, and Hodgkin's lymphoma (HL) were compared using Spearman's rank correlation coefficient and the Kruskal-Wallis test.

Results

The Ki-67 indices and ADC values were inversely correlated (r = -0.289, p = 0.0125); the differences in the Ki-67 index between aggressive NHL, indolent NHL, and HL were significant (p < 0.001); this was confirmed by the Nemenyi test except for indolent NHL vs. HL. The ADC values were significantly different between the types of lymphoma (p = 0.013); the Nemenyi test showed a significant difference only between aggressive NHL and HL.

Conclusions

The Ki-67 indices and ADC values are inversely correlated in patients with lymphoma, combining DWIBS and ADC values can evaluate the proliferation level of malignant lymphoma cells noninvasively.

Key points

• By using DWIBS, malignant lymphoma cell proliferation can be assessed noninvasively.
• The ADC value and Ki-67 index are significantly and inversely correlated.
• The ADC values were lower in aggressive NHL than in HL.
• The ADC values of aggressive and indolent NHL were not significantly different.
Literatur
1.
2.
Zurück zum Zitat Abdulqadhr G, Molin D, Aström G et al (2011) Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Acta Radiol 52:173–180CrossRefPubMed Abdulqadhr G, Molin D, Aström G et al (2011) Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Acta Radiol 52:173–180CrossRefPubMed
3.
Zurück zum Zitat Gu J, Chan T, Zhang J et al (2011) Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 197:W384–W391CrossRefPubMed Gu J, Chan T, Zhang J et al (2011) Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 197:W384–W391CrossRefPubMed
4.
Zurück zum Zitat Chen L, Liu M, Bao J et al (2013) The correlation between apparent diffusion coefficient and tumor cellularity in patients: a meta-analysis. PLoS One 8:e79008CrossRefPubMedPubMedCentral Chen L, Liu M, Bao J et al (2013) The correlation between apparent diffusion coefficient and tumor cellularity in patients: a meta-analysis. PLoS One 8:e79008CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Jeon JY, Chung HW, Lee MH et al (2016) Usefulness of diffusion-weighted MR imaging for differentiating between benign and malignant superficial soft tissue tumours and tumour-like lesions. Br J Radiol 89:20150929CrossRefPubMedPubMedCentral Jeon JY, Chung HW, Lee MH et al (2016) Usefulness of diffusion-weighted MR imaging for differentiating between benign and malignant superficial soft tissue tumours and tumour-like lesions. Br J Radiol 89:20150929CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Horger M, Claussen C, Kramer U et al (2014) Very early indicators of response to systemic therapy in lymphoma patients based on alterations in water diffusivity--a preliminary experience in 20 patients undergoing whole-body diffusion-weighted imaging. Eur J Radiol 83:1655–1664CrossRefPubMed Horger M, Claussen C, Kramer U et al (2014) Very early indicators of response to systemic therapy in lymphoma patients based on alterations in water diffusivity--a preliminary experience in 20 patients undergoing whole-body diffusion-weighted imaging. Eur J Radiol 83:1655–1664CrossRefPubMed
7.
Zurück zum Zitat Barajas RF Jr, Rubenstein JL, Chang JS et al (2010) Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 31:60–66CrossRefPubMed Barajas RF Jr, Rubenstein JL, Chang JS et al (2010) Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 31:60–66CrossRefPubMed
8.
Zurück zum Zitat Valles FE, Perez-Valles CL, Regalado S et al (2013) Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma. AJNR Am J Neuroradiol 34:35–40CrossRefPubMed Valles FE, Perez-Valles CL, Regalado S et al (2013) Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma. AJNR Am J Neuroradiol 34:35–40CrossRefPubMed
9.
10.
Zurück zum Zitat Broyde A, Boycov O, Strenov Y et al (2009) Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol 84:338–343CrossRefPubMed Broyde A, Boycov O, Strenov Y et al (2009) Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol 84:338–343CrossRefPubMed
11.
Zurück zum Zitat Cuenca X, Xhaard A, Mounier N (2009) Prognostic factors in Hodgkin and non-Hodgkin lymphomas. Bull Cancer 96:461–473PubMed Cuenca X, Xhaard A, Mounier N (2009) Prognostic factors in Hodgkin and non-Hodgkin lymphomas. Bull Cancer 96:461–473PubMed
12.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL et al (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France Swerdlow SH, Campo E, Harris NL et al (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France
13.
Zurück zum Zitat Huang HH, Xiao F, Chen FY et al (2012) Reassessment of the prognostic value of the International Prognostic Index and the revised InternationalPrognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study. Exp Ther Med 4:475–480CrossRefPubMedPubMedCentral Huang HH, Xiao F, Chen FY et al (2012) Reassessment of the prognostic value of the International Prognostic Index and the revised InternationalPrognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study. Exp Ther Med 4:475–480CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Sehn LH, Berry B, Chhanabhai M et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857–1861CrossRefPubMed Sehn LH, Berry B, Chhanabhai M et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857–1861CrossRefPubMed
15.
Zurück zum Zitat Prochazka KT, Melchardt T, Posch F et al (2016) NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients. Br J Cancer 115:1264–1272CrossRefPubMedPubMedCentral Prochazka KT, Melchardt T, Posch F et al (2016) NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients. Br J Cancer 115:1264–1272CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Gerdes J, Schwab U, Lemke H et al (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13–20CrossRefPubMed Gerdes J, Schwab U, Lemke H et al (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13–20CrossRefPubMed
17.
Zurück zum Zitat Jakovic LR, Mihaljevic BS, Jovanovic MD et al (2007) The expression of Ki-67 and Bcl-2 in Hodgkin's lymphoma: correlation with the International Prognostic Score and bulky disease: a study by the Serbian Lymphoma Study Group (SLG). Med Oncol 24:45–53CrossRefPubMed Jakovic LR, Mihaljevic BS, Jovanovic MD et al (2007) The expression of Ki-67 and Bcl-2 in Hodgkin's lymphoma: correlation with the International Prognostic Score and bulky disease: a study by the Serbian Lymphoma Study Group (SLG). Med Oncol 24:45–53CrossRefPubMed
18.
Zurück zum Zitat Hoster E, Rosenwald A, Berger F et al (2016) Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol 34:1386–1394CrossRefPubMed Hoster E, Rosenwald A, Berger F et al (2016) Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol 34:1386–1394CrossRefPubMed
20.
Zurück zum Zitat Huang Z, Xu X, Meng X et al (2015) Correlations between ADC values and molecular markers of Ki-67 and HIF-1α in hepatocellular carcinoma. Eur J Radiol 84:2464–2469CrossRefPubMed Huang Z, Xu X, Meng X et al (2015) Correlations between ADC values and molecular markers of Ki-67 and HIF-1α in hepatocellular carcinoma. Eur J Radiol 84:2464–2469CrossRefPubMed
21.
Zurück zum Zitat Meng X, Li H, Kong L et al (2016) MRI In rectal cancer: Correlations between MRI features and molecular markers Ki-67, HIF-1α, and VEGF. J Magn Reson Imaging 44:594–600CrossRefPubMed Meng X, Li H, Kong L et al (2016) MRI In rectal cancer: Correlations between MRI features and molecular markers Ki-67, HIF-1α, and VEGF. J Magn Reson Imaging 44:594–600CrossRefPubMed
22.
Zurück zum Zitat Guo AC, Cummings TJ, Dash RC et al (2002) Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 224:177–183CrossRefPubMed Guo AC, Cummings TJ, Dash RC et al (2002) Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 224:177–183CrossRefPubMed
23.
Zurück zum Zitat Wu X, Pertovaara H, Dastidar P et al (2013) ADC measurements in diffuse large B-cell lymphoma and follicular lymphoma: a DWI and cellularity study. Eur J Radiol 82:e158–e164CrossRefPubMed Wu X, Pertovaara H, Dastidar P et al (2013) ADC measurements in diffuse large B-cell lymphoma and follicular lymphoma: a DWI and cellularity study. Eur J Radiol 82:e158–e164CrossRefPubMed
24.
Zurück zum Zitat Fernebro J, Engellau J, Persson A et al (2007) Standardizing evaluation of sarcoma proliferation- higher Ki-67 expression in the tumor periphery than the center. APMIS 115:707–712CrossRefPubMed Fernebro J, Engellau J, Persson A et al (2007) Standardizing evaluation of sarcoma proliferation- higher Ki-67 expression in the tumor periphery than the center. APMIS 115:707–712CrossRefPubMed
Metadaten
Titel
Application of DWIBS in malignant lymphoma: correlation between ADC values and Ki-67 index
verfasst von
Mengtian Sun
Jingliang Cheng
Yong Zhang
Jie Bai
Feifei Wang
Yun Meng
Zhenqian Li
Publikationsdatum
15.11.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 4/2018
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-017-5135-y

Weitere Artikel der Ausgabe 4/2018

European Radiology 4/2018 Zur Ausgabe

Vascular-Interventional

In memoriam Prof. Erik Boijsen

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.